Molecular structure of Dinaciclib, CAS Number: 779353-01-4
Dinaciclib (CAS 779353-01-4)
See product citations (1)
Alternate Names:
1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-2S-piperidineethanol
Application:
Dinaciclib is a novel and potent cyclin-dependent kinase inhibitor for Cdk2, Cdk5, Cdk1, and Cdk9
CAS Number:
779353-01-4
Purity:
≥98%
Molecular Weight:
396.49
Molecular Formula:
C21H28N6O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Dinaciclib, classified as a small molecule inhibitor, exerts its inhibitory effects on cyclin-dependent kinases (CDKs). Belonging to the purine class of compounds, Dinaciclib has a molecular weight of approximately 441 Da. Notably, Dinaciclib demonstrates effectiveness in inhibiting various CDKs, including CDK4, CDK6, and CDK9. In laboratory applications, Dinaciclib has been employed to explore the repercussions of CDK inhibition on cellular processes such as cell proliferation, cell cycle progression, and gene expression. The mechanism of action for Dinaciclib involves targeting CDKs. CDKs are enzymes that play vital roles in cell cycle progression and gene expression. Dinaciclib effectively binds to the ATP binding site of CDKs, impeding their ability to phosphorylate their substrates. Consequently, this inhibition of CDK activity significantly hinders cell cycle progression and gene expression, offering valuable insights into the impact of CDK inhibition on cellular dynamics.
Dinaciclib (CAS 779353-01-4) References
- Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. | Parry, D., et al. 2010. Mol Cancer Ther. 9: 2344-53. PMID: 20663931
- Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. | Guzi, TJ., et al. 2011. Mol Cancer Ther. 10: 591-602. PMID: 21321066
- Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. | Abdullah, C., et al. 2011. Cell Cycle. 10: 977-88. PMID: 21358262
- The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. | Fu, W., et al. 2011. Mol Cancer Ther. 10: 1018-27. PMID: 21490307
- Dinaciclib for the treatment of breast cancer. | Criscitiello, C., et al. 2014. Expert Opin Investig Drugs. 23: 1305-12. PMID: 25107301
- Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. | Hossain, DMS., et al. 2018. J Clin Invest. 128: 644-654. PMID: 29337311
- Dinaciclib prolongs survival in the LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma. | Yang, J., et al. 2020. Am J Transl Res. 12: 1031-1043. PMID: 32269732
- Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. | Saqub, H., et al. 2020. Sci Rep. 10: 18489. PMID: 33116269
- Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. | Buzzetti, M., et al. 2021. Sci Rep. 11: 5374. PMID: 33686114
- Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer. | Howard, D., et al. 2021. Cancers (Basel). 13: PMID: 33800911
- CDK inhibitors in cancer therapy, an overview of recent development. | Zhang, M., et al. 2021. Am J Cancer Res. 11: 1913-1935. PMID: 34094661
- Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway. | Tsao, AN., et al. 2022. Oncol Rep. 47: PMID: 35417031
- Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer. | Howard, D., et al. 2022. Front Oncol. 12: 1014280. PMID: 36505806
- Sensitization of cervical cancer cells to radiation by the cyclin-dependent kinase inhibitor dinaciclib. | Zhang, H., et al. 2022. Med Oncol. 40: 68. PMID: 36586018
Inhibitor of:
1300002E11Rik, 1700018G05Rik, 4933404M19Rik, 4933411G11Rik, ALS2CR7, ANKRD20A1, ANKRD20A3, Arp7, BC024659, BEND6, Beta-NAP, C12orf50_1700017N19Rik, C12orf63, C2orf30, C430048L16Rik, C6orf1, CCDC77, CCNI2, CCNJL, CCRK, Cdc123, Cdc28, Cdc2L5, CDCrel-1, CDD, Cdk1, Cdk1/Cdk2, Cdk2, Cdk3, Cdk5, CDK5RAP, Cdk6, Cdk9, CdkL4, Cdx2, Cdx4, CENP-T, CINP, CIRP, Cks2, Ckt2, Clb2, CLIM-1, CNTD1, CPAN, CTF18, cyclin δ-1, cyclin δ-3, cyclin A, cyclin A-type, Cyclin A1, cyclin B, cyclin B1, cyclin C, cyclin D1, cyclin D3, cyclin E, cyclin E2, cyclin F, cyclin G1, cyclin I, cyclin J, cyclin L2, cyclin M2, cyclin T1, cyclin T2, cyclin Y, cyclin YL1, cyclin YL3, D14Ertd449e, Dcpp2, DLD, DNA pol δ 4, DNA pol κ, DOC1, E2F-1, E2F-7, E2F-8, EG435366, EG624855, ELL2, FAM111B, FAM127B, FLJ32549, FMIP, GAK, GEMC1, Gm355, Gm606, Gm75, GMD, GPN3, Gtlf3b, HemT-1, HEXIM2, HST, INCA1, Inv, IRF-2BP1, KBP, Ki-67, KIAA1267, Kin28, KKIALRE, KPRP, L-Myc, LIN37, LOC341346, MCEMP1, Mcpr1, MIPU1, Mog1p, MPc3_CBX8, MPHOSPH8, Myc1, MYCBP, NIF3L1 BP1, Olr559, OTTMUSG00000016588, p107, p14 ARF/p16, p18, p27, p35, p39 (CDK5R), p57, PCTAIRE-2, Peregrin, Pho85, PHR1, PISSLRE, PITSLRE A, PITSLRE B, POC5, POGZ, Pol II, PRAMEF10, PREI4, PRRT4, RIOK2, RMP, ROGDI, SERTAD3, SERTAD4, SHPRH, Sic1, Sil, SPC12, Speedy A, Speedy E3, Speedy E6, TAFII-18, TEX27, TMEM194, Treslin, TSGA10IP, V1RG1, WDR24, WDR51B, WDR66, YY1AP1, ZFP260, ZHX3, ZNF2, ZNF20, ZNF705A, ZSCAN16, and ZWINT.Activator of:
AFF4, CCRK, Cdk10, Cdk8, Cdk9, Cig2, Cks1, CLK4, cyclin δ-1, cyclin YL3, DP-1, NELF-B, Snk, SOLO, Speedy A, SSBP3, WDR61, and ZNF347.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dinaciclib, 5 mg | sc-364483 | 5 mg | $247.00 | |||
Dinaciclib, 25 mg | sc-364483A | 25 mg | $888.00 |